CONTEXT: States of acute and chronic energy deficit are characterized by increased GH secretion and decreased IGF-I levels. OBJECTIVE: The objective of the study was to determine whether changes in levels of leptin, a key mediator of the adaptation to starvation, regulate the GH-IGF system during energy deficit. DESIGN, SETTING, PATIENTS, AND INTERVENTION: We studied 14 healthy normal-weight men and women during three conditions: baseline fed and 72-h fasting (to induce hypoleptinemia) with administration ofplacebo or recombinant methionyl human leptin (r-metHuLeptin) (to reverse the fasting associated hypoleptinemia). We also studied eight normal-weight women with exercise-induced chronic energy deficit and hypothalamic amenorrhea at baseline and during 2-3 months of r-metHuLeptin treatment. MAIN OUTCOME MEASURES: GH pulsatility, IGF levels, IGF and GH binding protein (GHBP) levels were measured. RESULTS: During short-term energy deficit, measures of GH pulsatility and disorderliness and levels of IGF binding protein (IGFBP)-1 increased, whereas leptin, insulin, IGF-I (total and free), IGFBP-4, IGFBP-6, and GHBP decreased; r-metHuLeptin administration blunted the starvation-associated decrease of IGF-I. In chronic energy deficit, total and free IGF-I, IGFBP-6, and GHBP levels were lower, compared with euleptinemic controls; r-metHuLeptin administration had no major effect on GH pulsatility after 2 wk but increased total IGF-I levels and tended to increase free IGF-I and IGFBP-3 after 1 month. CONCLUSIONS: The GH/IGF system changes associated with energy deficit are largely independent of leptin deficiency. During acute energy deficit, r-metHuLeptin administration in replacement doses blunts the starvation-induced decrease of IGF-I, but during chronic energy deficit, r-metHuLeptin administration increases IGF-I and tends to increase free IGF-I and IGFBP-3.
RCT Entities:
CONTEXT: States of acute and chronic energy deficit are characterized by increased GH secretion and decreased IGF-I levels. OBJECTIVE: The objective of the study was to determine whether changes in levels of leptin, a key mediator of the adaptation to starvation, regulate the GH-IGF system during energy deficit. DESIGN, SETTING, PATIENTS, AND INTERVENTION: We studied 14 healthy normal-weight men and women during three conditions: baseline fed and 72-h fasting (to induce hypoleptinemia) with administration of placebo or recombinant methionyl humanleptin (r-metHuLeptin) (to reverse the fasting associated hypoleptinemia). We also studied eight normal-weight women with exercise-induced chronic energy deficit and hypothalamic amenorrhea at baseline and during 2-3 months of r-metHuLeptin treatment. MAIN OUTCOME MEASURES: GH pulsatility, IGF levels, IGF and GH binding protein (GHBP) levels were measured. RESULTS: During short-term energy deficit, measures of GH pulsatility and disorderliness and levels of IGF binding protein (IGFBP)-1 increased, whereas leptin, insulin, IGF-I (total and free), IGFBP-4, IGFBP-6, and GHBP decreased; r-metHuLeptin administration blunted the starvation-associated decrease of IGF-I. In chronic energy deficit, total and free IGF-I, IGFBP-6, and GHBP levels were lower, compared with euleptinemic controls; r-metHuLeptin administration had no major effect on GH pulsatility after 2 wk but increased total IGF-I levels and tended to increase free IGF-I and IGFBP-3 after 1 month. CONCLUSIONS: The GH/IGF system changes associated with energy deficit are largely independent of leptin deficiency. During acute energy deficit, r-metHuLeptin administration in replacement doses blunts the starvation-induced decrease of IGF-I, but during chronic energy deficit, r-metHuLeptin administration increases IGF-I and tends to increase free IGF-I and IGFBP-3.
Authors: Ana Cristina Palacio; Francisco Pérez-Bravo; José Luis Santos; Liana Schlesinger; Fernando Monckeberg Journal: Nutrition Date: 2002-01 Impact factor: 4.008
Authors: Ken H Darzy; Robert D Murray; Helena K Gleeson; Suzan S Pezzoli; Michael O Thorner; Stephen M Shalet Journal: J Clin Endocrinol Metab Date: 2005-12-29 Impact factor: 5.958
Authors: M A Llopis; M L Granada; G Cuatrecasas; X Formiguera; L Sánchez-Planell; A Sanmartí; A Alastrué; M Rull; A Corominas; M Foz Journal: J Clin Endocrinol Metab Date: 1998-06 Impact factor: 5.958
Authors: Maria T Vamvini; Konstantinos N Aronis; John P Chamberland; Christos S Mantzoros Journal: J Clin Endocrinol Metab Date: 2011-08-24 Impact factor: 5.958
Authors: Christos S Mantzoros; Faidon Magkos; Mary Brinkoetter; Elizabeth Sienkiewicz; Tina A Dardeno; Sang-Yong Kim; Ole-Petter R Hamnvik; Anastasia Koniaris Journal: Am J Physiol Endocrinol Metab Date: 2011-07-26 Impact factor: 4.310
Authors: Jonathan D Douros; David A Baltzegar; Jamie Mankiewicz; Jordan Taylor; Yoko Yamaguchi; Darren T Lerner; Andre P Seale; E Gordon Grau; Jason P Breves; Russell J Borski Journal: Gen Comp Endocrinol Date: 2016-07-19 Impact factor: 2.822
Authors: M W Hamrick; A Dukes; P Arounleut; C Davis; S Periyasamy-Thandavan; S Mork; S Herberg; M H Johnson; C M Isales; W D Hill; L Otvos; E J Belin de Chantemèle Journal: Exp Gerontol Date: 2015-07-26 Impact factor: 4.032